{"gene":"MST1R","run_date":"2026-06-10T02:59:51","timeline":{"discoveries":[{"year":1994,"finding":"RON is a heterodimeric receptor tyrosine kinase: the single-chain precursor is glycosylated, cleaved into a 185 kDa disulfide-linked heterodimer (35 kDa alpha + 150 kDa beta chains), and the beta-chain displays intrinsic tyrosine kinase activity in vitro. MSP (macrophage stimulating protein), a HGF homologue, specifically activates RON by inducing tyrosine phosphorylation, leading to DNA synthesis in epithelial cells. HGF does not activate RON, nor does MSP activate the HGF receptor.","method":"Immunoprecipitation, in vitro kinase assay, ligand stimulation assays, biochemical cross-reactivity experiments","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase assay with immunoprecipitation, confirmed ligand specificity with reciprocal negative controls, replicated in a concurrent independent study (PMID:7939629)","pmids":["8062829"],"is_preprint":false},{"year":1994,"finding":"The RON gene product is confirmed as the specific cell-surface receptor for MSP: 125I-MSP cross-links to a 220 kDa complex (MSP + RON beta chain) in RON-transfected MDCK cells, MSP binding is competed by unlabeled MSP but not by HGF-SF, MSP induces phosphorylation of the RON beta chain, and triggers cell migration.","method":"Radioligand binding, chemical cross-linking, immunoprecipitation, cell migration assay","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct ligand-receptor binding with cross-linking and immunoprecipitation, negative control with HGF, replicated by concurrent independent study (PMID:8062829)","pmids":["7939629"],"is_preprint":false},{"year":2000,"finding":"MET and RON receptors form non-covalent complexes on the cell surface and undergo direct transphosphorylation: ligand-activated MET transphosphorylates RON (and vice versa) at both kinase-activating tyrosines (Y1238/Y1239 in RON) and signal transducer docking sites (Y1353/Y1360 in RON). This cross-talk is restricted to the scatter factor receptor subfamily and does not occur with ErbB1, ErbB2, or TrkA. A kinase-inactive RON acts as a dominant negative suppressor of oncogenic MET mutants.","method":"Kinase-inactive mutant receptor expression, cell-surface cross-linking, phosphorylation site mapping, focus-formation transformation assay","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution with defined kinase-dead mutants, phosphorylation site specificity mapped, negative controls with unrelated RTKs, dominant negative rescue experiment","pmids":["10871856"],"is_preprint":false},{"year":2001,"finding":"Oncogenic mutants of RON cause tyrosine phosphorylation and accumulation of beta-catenin, constitutive activation of Tcf transcription factor, and increased c-myc and cyclin D1 expression. Interference with the beta-catenin pathway reduces the transforming potential of mutant RON, establishing beta-catenin/Tcf as a downstream oncogenic signaling pathway of RON.","method":"Transfection of oncogenic RON mutants, beta-catenin tyrosine phosphorylation assay, Tcf luciferase reporter, Western blot, dominant-negative pathway interference","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (phosphorylation, reporter assay, protein level, dominant negative rescue), confirmed in multiple cell lines","pmids":["11486025"],"is_preprint":false},{"year":2001,"finding":"Point mutations in RON analogous to oncogenic MET mutations (hereditary papillary renal carcinoma) result in constitutive RON phosphorylation, cellular transformation in NIH3T3 cells, in vivo tumor formation, and lung metastasis in experimental metastasis models.","method":"Site-directed mutagenesis, NIH3T3 transformation assay, in vivo tumor formation, experimental metastasis model","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — mutagenesis with in vitro and in vivo functional validation across multiple mutants","pmids":["11593422"],"is_preprint":false},{"year":2003,"finding":"The sema domain of RON participates in MSP ligand binding by the full-length receptor. A soluble secreted sema domain fragment (ron-sema) exerts a dominant negative effect on MSP-induced RON activation, inhibiting downstream signaling pathways and MSP-dependent cellular responses including proliferation.","method":"Soluble sema domain expression, dominant-negative phosphorylation assay, cell proliferation assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional domain mapped by dominant-negative secreted fragment with signaling and cellular readouts, single lab","pmids":["14597639"],"is_preprint":false},{"year":2003,"finding":"RON and EGFR physically associate (co-immunoprecipitate) in NIH3T3 cells; ligand stimulation of either RON (with HGFL) or EGFR (with EGF) induces phosphorylation of both receptors. Dominant-negative EGFR suppresses RON-induced cell scatter, and dominant-negative RON suppresses EGFR-induced focus formation, establishing functional cross-talk between these heterologous RTKs.","method":"Co-immunoprecipitation, Western phosphorylation assay, dominant-negative co-transfection, cell scatter assay, focus formation assay","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP plus dominant-negative functional rescue, single lab","pmids":["14499632"],"is_preprint":false},{"year":2004,"finding":"A truncated RON variant (sf-RON) lacking most of the extracellular domain but retaining the transmembrane and intracellular domains is constitutively phosphorylated and has strong intrinsic tyrosine kinase activity. Epithelial cells transduced with sf-RON lose E-cadherin expression through a dominant transcriptional repression pathway mediated by the transcription factor SLUG, inducing EMT and an aggressive phenotype.","method":"Retroviral transduction, Western blot, kinase assay, morphological analysis, anchorage-independent growth, SLUG expression analysis","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — constitutive activity confirmed biochemically, EMT mechanism traced to SLUG, single lab with multiple phenotypic readouts","pmids":["15289319"],"is_preprint":false},{"year":1999,"finding":"MSP/RON signaling activates multiple distinct intracellular kinase pathways: FAK, c-Src, AKT, MAPK, and JNK are rapidly activated by MSP. MAPK and c-Src operate in one cascade (MAPK downstream of c-Src) mediating cell proliferation; FAK mediates proliferation via a separate pathway; PI3K/AKT mediates anti-apoptotic effects; PI3K regulates adhesion and motility via AKT-independent downstream components.","method":"In vitro kinase assays, pharmacological inhibition, dominant-negative expression, MSP stimulation time-course","journal":"Journal of leukocyte biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple kinase pathways mapped with inhibitors and dominant negatives, single lab","pmids":["10080538"],"is_preprint":false},{"year":2004,"finding":"RON functions downstream of the erythropoietin receptor (EpoR) in erythroid progenitor expansion: Gab1 is constitutively associated with RON; EPO activates RON, which phosphorylates Gab1, MAPK, and PKB/AKT (but not STAT5). RON activation is sufficient to replace EPO in progenitor expansion but not in differentiation.","method":"Co-immunoprecipitation, phosphorylation assays, EPO receptor signaling epistasis, ex vivo erythroid progenitor expansion assay","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — constitutive RON-Gab1 association by co-IP, functional epistasis (RON downstream of EpoR) with defined readouts, single lab","pmids":["14982882"],"is_preprint":false},{"year":2008,"finding":"RON activation by MSP inhibits IFN-γ-induced STAT1 phosphorylation and CIITA expression in macrophages, reducing surface MHC class II levels. MSP/RON signaling induces suppressor of cytokine signaling 1 (SOCS1), providing a mechanistic explanation for RON-mediated inhibition of IFN-γ responses. In RON(-/-) mice, the enhanced susceptibility to LPS challenge is dependent on IFN-γ signaling (shown by RON/IFN-γR double knockout rescue).","method":"Primary macrophage stimulation, STAT1 phosphorylation assay, CIITA expression analysis, SOCS1 induction, genetic epistasis with double-knockout mice","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — biochemical mechanism (SOCS1 induction, STAT1 inhibition) plus genetic epistasis with double-knockout, multiple orthogonal methods","pmids":["18684919"],"is_preprint":false},{"year":2010,"finding":"RON activation by MSP induces arginase I (Arg1) expression in macrophages through an AP-1 site located 433 bp upstream of the Arg1 transcription start site, via MAPK activation, Fos upregulation, and Fos binding to the AP-1 site. This mechanism is Stat6-independent. In vivo, Arg1 expression in tumor-associated macrophages is reduced in Ron(-/-) mice and is associated with reduced syngeneic tumor growth.","method":"Arg1 promoter analysis, chromatin immunoprecipitation (Fos binding to AP-1), MAPK activation assay, Ron(-/-) mouse model, tumor growth assay","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — promoter mechanism mapped by ChIP and AP-1 site identification, in vivo validation with knockout mice, multiple orthogonal methods","pmids":["21810604"],"is_preprint":false},{"year":2010,"finding":"RON negatively regulates TNF-alpha production in alveolar macrophages by inhibiting NF-κB activation and increasing IκB levels following LPS challenge. RON activation also negatively regulates Adam17 (the metalloprotease responsible for TNF-alpha processing), establishing RON as a regulator of both TNF-alpha production and shedding.","method":"Primary alveolar macrophage stimulation, NF-κB activity assay, IκB Western blot, Adam17 expression analysis, MH-S alveolar macrophage cell line","journal":"Shock","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple signaling nodes (NF-κB, IκB, Adam17) examined in primary cells and cell line, single lab","pmids":["19487969"],"is_preprint":false},{"year":2011,"finding":"In MET-amplified and MET-addicted cancer cells, activated MET specifically transphosphorylates RON kinase. RON phosphorylation is suppressed by MET-specific kinase inhibitors (PHA-665752 or JNJ-38877605) or by antibody-induced shedding of cell-surface MET. shRNA silencing of RON in MET-addicted cells decreases proliferation, clonogenic activity in vitro, and tumorigenicity in vivo, establishing RON transactivation as a component of MET oncogene addiction.","method":"Phosphorylation assays, MET-specific kinase inhibitors, antibody-induced MET shedding, shRNA knockdown, in vitro clonogenic assay, in vivo xenograft","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple pharmacological and genetic approaches to confirm MET→RON transphosphorylation, in vitro and in vivo functional validation, single lab with multiple orthogonal methods","pmids":["21212418"],"is_preprint":false},{"year":2010,"finding":"RON signaling in macrophages suppresses LPS-induced TNF-α production while in hepatocytes it inhibits cell survival. Conditional Ron deletion studies show: Ron loss in hepatocytes leads to less liver damage and increased survival, whereas Ron loss in macrophages leads to increased cytokine production that is toxic to hepatocytes. TK(-/-) Kupffer cells produce more TNF-α after LPS, and conditioned media from these cells is more hepatotoxic.","method":"Cell-type-specific conditional Ron deletion (hepatocyte- and macrophage-specific Cre), purified primary cell cultures, conditioned media transfer assay, in vivo liver injury model","journal":"Hepatology","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific conditional knockouts with orthogonal in vitro and in vivo validation, mechanistic dissection of Kupffer cell vs. hepatocyte contributions","pmids":["21520175"],"is_preprint":false},{"year":2012,"finding":"RON interacts with plectin and integrin-β4 (ITGB4) in pancreatic cancer cells. Upon MSP stimulation, RON binds to plectin and ITGB4, disrupting the plectin-ITGB4 interaction that normally anchors hemidesmosomes to the extracellular matrix. This disruption enhances cell migration in a manner dependent on RON and PI3K activity, but not MEK.","method":"Multidimensional protein identification analysis (MudPIT), co-immunoprecipitation, shRNA knockdown, cell migration assay, pharmacological PI3K/MEK inhibition","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — novel RON-plectin-ITGB4 complex identified by MS and confirmed by co-IP, functional validation by shRNA and inhibitors, single lab","pmids":["22275185"],"is_preprint":false},{"year":2011,"finding":"IGF-1R physically interacts with RON in pancreatic cancer cells. IGF-1 induces rapid phosphorylation of RON, but RON signaling does not activate IGF-1R (unidirectional signaling). IGF-1-induced pancreatic cancer cell migration is RON-dependent: shRNA knockdown of RON or RON kinase inhibitor abrogates IGF-1-induced wound closure. In pancreatic cancer cells, IGF-1 activates STAT3 in a RON-dependent manner.","method":"MudPIT proteomics, co-immunoprecipitation, shRNA knockdown, kinase inhibitor, scratch wound migration assay, STAT3 phosphorylation assay","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — interaction confirmed by MS and co-IP, directional signaling established, functional migration assay with genetic and pharmacological RON inhibition, single lab","pmids":["21565828"],"is_preprint":false},{"year":2014,"finding":"RON/MSP signaling promotes breast cancer metastasis through an epigenetic reprogramming pathway: via PI3K signaling, RON/MSP induces expression of the DNA glycosylase MBD4, which drives aberrant DNA methylation at specific loci misregulating a defined gene set. MBD4 glycosylase catalytic activity is required for RON/MSP-driven metastasis. Knockdown of MBD4 reverses methylation and blocks metastasis.","method":"shRNA knockdown, MBD4 catalytic mutant rescue, methylation profiling, PI3K inhibition, in vivo metastasis assay, patient-derived xenograft pharmacological RON inhibition","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — catalytic mutant rescue establishes mechanistic requirement for MBD4 enzymatic activity, multiple orthogonal methods including in vivo PDX model, methylation profiling links signaling to epigenetic output","pmids":["24388747"],"is_preprint":false},{"year":2009,"finding":"A novel soluble RON splice variant (RONDelta90), generated by skipping exon 6 causing a frameshift and premature termination in exon 7, is secreted as a truncated soluble protein. RONDelta90 inhibits MSP-induced phosphorylation of full-length cellular RON, attenuates basal RON activation, and inhibits MSP-induced glioma cell migration and random motility, functioning as an endogenous antagonist.","method":"RT-PCR, cDNA cloning, recombinant protein expression and purification, RON phosphorylation inhibition assay, cell migration assay","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — novel splice variant cloned and expressed recombinantly, functional antagonism demonstrated with biochemical and cell migration assays, single lab","pmids":["19519771"],"is_preprint":false},{"year":2008,"finding":"RON promotes MSP-independent cell survival, increased cell spreading, and enhanced migration in response to other growth factors when expressed in MCF-10A breast epithelial cells. Both MSP-dependent and MSP-independent RON signaling are mediated in part by Src family kinases. RON-mediated proliferation and directional migration require MSP, but survival and spreading do not.","method":"RON overexpression in MCF-10A cells, Src family kinase inhibition, cell survival assay, spreading assay, migration assay with/without MSP","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ligand-dependent vs. independent signaling modes dissected in isogenic system with pharmacological inhibition, single lab","pmids":["18836480"],"is_preprint":false},{"year":2014,"finding":"Under hypoxic conditions, RON translocates to the nucleus of cancer cells. Nuclear RON interacts with HIF-1α in a manner dependent on RON tyrosine kinase activity, binds the c-JUN promoter, and activates c-JUN transcription. Nuclear RON plays a more important role than HIF-1α in c-JUN promoter activation, promoting cancer cell survival, proliferation, and tumorigenicity under hypoxia.","method":"Cell fractionation, co-immunoprecipitation of nuclear RON with HIF-1α, chromatin immunoprecipitation at c-JUN promoter, kinase-dead mutant, reporter assay, functional proliferation/survival assays under hypoxia","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — nuclear localization confirmed by fractionation, HIF-1α interaction by co-IP, promoter binding by ChIP, kinase-dependence by kinase-dead mutant, multiple functional readouts","pmids":["24903148"],"is_preprint":false},{"year":2008,"finding":"RON represses HIV-1 transcription at multiple checkpoints: RON expression decreases NF-κB and RNA Pol II binding to the HIV LTR, reduces RNA Pol II processivity at sequences downstream of the transcription start site, and increases binding of negative elongation factors NELF, Spt5, and Pcf11. RON-mediated repression is sensitive to HDAC inhibition and is associated with nucleosome remodeling.","method":"Chromatin immunoprecipitation (ChIP) for transcription factors and Pol II at HIV LTR, elongation factor binding assay, HDAC inhibitor treatment, nucleosome remodeling analysis","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-based mechanism mapping at multiple transcriptional checkpoints, single lab","pmids":["18209063"],"is_preprint":false},{"year":2002,"finding":"RON activation by MSP inhibits LPS-induced apoptosis of macrophages by suppressing nitric oxide production and p53 accumulation. The anti-apoptotic effect of RON requires PI3K activity, as demonstrated by wortmannin inhibition and dominant-negative PI3K p85 subunit expression.","method":"Primary peritoneal macrophage assay, NO measurement, p53 Western blot, wortmannin pharmacological inhibition, dominant-negative PI3K p85 expression, apoptosis assay","journal":"Journal of leukocyte biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanism traced to PI3K/p53/NO axis using both pharmacological and dominant-negative genetic approaches, single lab","pmids":["11818458"],"is_preprint":false},{"year":2011,"finding":"EBV latent membrane protein 1 (LMP1) enhances RON expression through its C-terminal activation region-1 (CTAR1) by promoting NF-κB binding to the RON promoter. RON is expressed in EBV-transformed lymphoblastoid cell lines (LCLs) but not primary B cells; RON knockdown decreases LCL proliferation, and RON re-expression compensates for growth inhibition caused by LMP1 knockdown.","method":"NF-κB binding to RON promoter assay, LMP1 CTAR1 domain mapping, shRNA knockdown, rescue overexpression, proliferation assay","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter mechanism mapped, functional epistasis between LMP1 and RON established by knockdown-rescue, single lab","pmids":["21659546"],"is_preprint":false},{"year":2020,"finding":"The splicing factor HNRNPA2B1 mediates exclusion of cassette exon 11 from MST1R pre-mRNA, producing the RON∆165 isoform. CRISPR/Cas9 knockout of HNRNPA2B1 reduces RON∆165 production (confirmed by minigene assay), decreases Akt/PKB signaling, upregulates E-cadherin and downregulates vimentin, reducing EMT. HNRNPA2B1 overexpression in KO cells rescues RON∆165 expression and restores Akt activation and EMT.","method":"CRISPR/Cas9 knockout, minigene splicing reporter assay, Western blot, EMT marker analysis, rescue overexpression","journal":"Laboratory investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — splice mechanism validated by minigene, CRISPR KO with functional rescue, multiple downstream markers, single lab","pmids":["32669614"],"is_preprint":false},{"year":2017,"finding":"MSP signals through RON expressed on osteoclast precursors to activate osteoclasts by a pathway complementary to RANKL signaling and converging on SRC kinase. Genetic or pharmacological inhibition of RON kinase blocks cancer-mediated bone destruction and osteoporosis in multiple mouse models. Clinical trial data show that a RON kinase inhibitor (BMS-777607/ASLAN002) alters markers of bone turnover in cancer patients.","method":"Genetic RON deletion, pharmacological RON inhibition, multiple mouse osteolysis models, SRC pathway analysis, clinical biomarker analysis","journal":"Science translational medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple mouse model systems with both genetic and pharmacological inhibition, SRC convergence identified, clinical biomarker validation in human trial","pmids":["28123075"],"is_preprint":false},{"year":2018,"finding":"RON activation by MSP in macrophages upregulates surface levels of CD80 and PD-L1 (ligands for CTLA-4 and PD-1 on T cells). Genetic deletion or pharmacological inhibition of RON combined with anti-CTLA-4 (but not anti-PD-1) results in complete tumor eradication in ~46% of animals, associated with higher T-cell activation and tumor-infiltrating lymphocytes.","method":"Flow cytometry for CD80/PD-L1 surface expression, genetic Ron deletion, pharmacological inhibition, orthotopic tumor transplantation, combination immunotherapy study, T-cell activation markers","journal":"Oncoimmunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — mechanism (CD80/PD-L1 upregulation) linked to immune outcome, genetic and pharmacological RON inhibition, in vivo therapeutic validation, selectivity for anti-CTLA-4 over anti-PD-1 established","pmids":["30228950"],"is_preprint":false},{"year":2010,"finding":"RON knockdown in HCT116 colon cancer cells (heterozygous for PIK3CA H1047R gain-of-function mutation) reduces mutant PI3K activity and AKT phosphorylation, sensitizes cells to growth factor deprivation-induced apoptosis, and significantly reduces lung metastasis in orthotopic models. This establishes RON as an upstream activator of mutant PI3K in colon cancer.","method":"siRNA knockdown, PI3K activity assay, AKT phosphorylation, caspase-3/DNA fragmentation apoptosis assay, orthotopic metastasis model","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RON-PI3K signaling link demonstrated biochemically and functionally in vitro and in vivo, single lab","pmids":["19224914"],"is_preprint":false},{"year":2007,"finding":"MSP stimulation of pancreatic cancer cells results in increased phosphorylation of MAPK and AKT via RON, promotes migration and invasion in a dose-dependent manner, and RON inhibition by monoclonal antibody reverses these effects. RON activation leads to E-cadherin loss and nuclear translocation of beta-catenin (consistent with EMT).","method":"Western blot for phospho-MAPK and phospho-AKT, migration/invasion assay, RON monoclonal antibody blockade, E-cadherin immunofluorescence, beta-catenin localization","journal":"Cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple signaling and phenotypic readouts, antibody blockade confirms RON specificity, single lab","pmids":["17311308"],"is_preprint":false},{"year":2009,"finding":"RON positively regulates production of angiogenic chemokines in prostate cancer cells through NF-κB signaling. RON knockdown decreases NF-κB activation and angiogenic chemokine production; Ron overexpression in LNCaP cells increases chemokines, which can be abrogated by NF-κB inhibition. RON knockdown reduces endothelial cell chemotaxis in vitro and reduces tumor microvessel density in vivo.","method":"shRNA knockdown, NF-κB activity assay, chemokine ELISA, endothelial cell chemotaxis assay, orthotopic xenograft with microvessel density","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — NF-κB pathway mapped with both knockdown and overexpression, in vitro and in vivo validation, single lab","pmids":["19838218"],"is_preprint":false},{"year":2015,"finding":"A novel RON isoform (P5P6), arising from partial splicing of exons 5 and 6 and lacking the first extracellular IPT domain, is constitutively phosphorylated, localizes to cytoplasm and traffics to plasma membrane, and activates AKT (and MAPK in some cell types). P5P6 transforms NIH3T3 cells and induces tumorigenicity in immortalized human pancreatic duct epithelial (HPDE) cells.","method":"RT-PCR, mass spectrometry peptide confirmation, Western blot, subcellular fractionation, kinase inhibitor, NIH3T3 transformation assay, in vivo tumor formation","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — protein isoform confirmed by MS, constitutive activation and localization characterized biochemically, transformation validated in vitro and in vivo, single lab","pmids":["26477314"],"is_preprint":false},{"year":1998,"finding":"The mouse Ron gene contains 19 exons spanning ~13.2 kb. Two promoter regions (nucleotides -585 to -465 and -465 to -285) are critical for Ron expression in epithelial cells, and gel mobility shift assays indicate specific protein binding at -585 to -508 (negative regulation) and -375 to -285 (positive regulation).","method":"Genomic library screening, primer extension, deletion reporter gene constructs (CAT assay), transient transfection, gel mobility shift assay","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter elements defined by deletion analysis with gel shift confirmation, single lab","pmids":["9467940"],"is_preprint":false}],"current_model":"MST1R/RON is a heterodimeric receptor tyrosine kinase (35 kDa alpha + 150 kDa beta chains) activated by its specific ligand MSP, which induces beta-chain transautophosphorylation and recruits multiple downstream signaling cascades including PI3K/AKT, MAPK/ERK, c-Src, FAK, beta-catenin/TCF, and NF-κB; RON forms non-covalent complexes with MET on the cell surface enabling bidirectional transphosphorylation and cross-talk with EGFR, IGF-1R, and the EpoR, and can also translocate to the nucleus under hypoxia to directly activate c-JUN transcription; in macrophages, MSP/RON signaling suppresses inflammatory responses by inducing SOCS1 to inhibit STAT1, blocking NF-κB/Adam17-dependent TNF-α production, and upregulating arginase I via AP-1 to promote M2 polarization, while also regulating CD80/PD-L1 surface expression to modulate antitumor immunity; constitutively active truncated and alternatively spliced RON isoforms (sfRON, RONDelta160, RONDelta165, P5P6) drive EMT through SLUG-mediated E-cadherin repression and activate AKT-dependent oncogenic programs, and RON/MSP promotes metastasis through a PI3K→MBD4 epigenetic reprogramming pathway."},"narrative":{"mechanistic_narrative":"MST1R (RON) is a heterodimeric receptor tyrosine kinase whose intracellular β-chain is activated by the HGF-homologue MSP, driving epithelial DNA synthesis, migration, proliferation, and survival [PMID:8062829, PMID:7939629]. Ligand binding requires the receptor sema domain, and a soluble sema fragment acts as a dominant-negative antagonist [PMID:14597639]. Activated RON couples to a branched signaling network — FAK, c-Src/MAPK, JNK, and PI3K/AKT — in which c-Src/MAPK and FAK drive proliferation while PI3K/AKT confers anti-apoptotic and motility outputs [PMID:10080538, PMID:18836480], and engages the β-catenin/Tcf axis to induce c-myc and cyclin D1 during oncogenic transformation [PMID:11486025]. RON cooperates with other receptor tyrosine kinases: it forms non-covalent surface complexes with MET enabling bidirectional transphosphorylation, and RON transactivation contributes to MET oncogene addiction [PMID:10871856, PMID:21212418]; it also physically associates with and is transphosphorylated by EGFR and IGF-1R [PMID:14499632, PMID:21565828]. Oncogenic point mutations and constitutively active truncated/spliced isoforms (sf-RON, P5P6, RONΔ165) signal ligand-independently through AKT and repress E-cadherin via SLUG to drive EMT and tumorigenesis [PMID:11593422, PMID:15289319, PMID:26477314, PMID:32669614], and RON/MSP promotes metastasis through a PI3K→MBD4 epigenetic reprogramming pathway requiring MBD4 glycosylase activity [PMID:24388747]. Under hypoxia, RON translocates to the nucleus, interacts with HIF-1α, and directly activates c-JUN transcription in a kinase-dependent manner [PMID:24903148]. In macrophages, MSP/RON signaling is broadly immunosuppressive: it induces SOCS1 to inhibit IFN-γ/STAT1 responses [PMID:18684919], blocks NF-κB- and Adam17-dependent TNF-α production [PMID:19487969, PMID:21520175], upregulates arginase I via an AP-1/Fos mechanism [PMID:21810604], and modulates CD80/PD-L1 surface expression to restrain antitumor immunity [PMID:30228950]. RON additionally activates osteoclasts through a SRC-convergent pathway driving cancer-associated bone destruction [PMID:28123075].","teleology":[{"year":1994,"claim":"Established RON as a bona fide receptor tyrosine kinase and identified MSP as its specific ligand, defining the core receptor-ligand axis distinct from the HGF/MET system.","evidence":"Immunoprecipitation, in vitro kinase assay, radioligand cross-linking, and reciprocal ligand-specificity controls in transfected epithelial cells","pmids":["8062829","7939629"],"confidence":"High","gaps":["Downstream effector cascades not yet mapped","Physiological tissue contexts unaddressed"]},{"year":1998,"claim":"Defined the genomic structure and transcriptional control elements of the Ron gene, providing the basis for understanding context-specific expression.","evidence":"Genomic library screening, deletion-reporter CAT assays, and gel mobility shift assays of mouse promoter regions","pmids":["9467940"],"confidence":"Medium","gaps":["Specific trans-acting transcription factors not identified","Human promoter not characterized in this study"]},{"year":1999,"claim":"Resolved the branched intracellular signaling architecture downstream of RON, separating proliferative from survival and motility outputs.","evidence":"In vitro kinase assays with pharmacological inhibitors and dominant-negative constructs across MSP time-courses","pmids":["10080538"],"confidence":"Medium","gaps":["Direct adaptor docking events not mapped","Single-lab pathway dissection"]},{"year":2001,"claim":"Showed that oncogenic RON mutants transform cells and metastasize, and that β-catenin/Tcf is a required downstream oncogenic effector, linking RON activation to transcriptional programs.","evidence":"Oncogenic mutant transfection, β-catenin phosphorylation, Tcf reporter assays, NIH3T3 transformation, and in vivo metastasis models","pmids":["11486025","11593422"],"confidence":"High","gaps":["Mechanism of β-catenin tyrosine phosphorylation not defined","Relevance of specific mutations to human tumors not established"]},{"year":2000,"claim":"Demonstrated that RON and MET form surface complexes with bidirectional transphosphorylation, establishing cross-talk within the scatter-factor receptor subfamily.","evidence":"Kinase-inactive mutants, cell-surface cross-linking, phosphosite mapping, and dominant-negative focus-formation assays","pmids":["10871856"],"confidence":"High","gaps":["Stoichiometry of MET-RON complexes not defined","In vivo relevance not addressed in this study"]},{"year":2002,"claim":"Identified the immunoregulatory anti-apoptotic role of RON in macrophages, mediated by PI3K-dependent suppression of NO and p53.","evidence":"Primary macrophage apoptosis assays with wortmannin and dominant-negative PI3K p85","pmids":["11818458"],"confidence":"Medium","gaps":["Direct PI3K recruitment site on RON not mapped","Single-lab finding"]},{"year":2004,"claim":"Showed that constitutively active truncated sf-RON drives EMT through SLUG-mediated E-cadherin repression, revealing how aberrant RON isoforms produce aggressive phenotypes.","evidence":"Retroviral transduction, kinase assays, morphological and anchorage-independent growth assays with SLUG analysis","pmids":["15289319"],"confidence":"Medium","gaps":["Mechanism of SLUG induction by RON not defined","Single-lab study"]},{"year":2004,"claim":"Placed RON downstream of the erythropoietin receptor in erythroid progenitor expansion via constitutive Gab1 association, broadening RON's physiological signaling partnerships.","evidence":"Co-IP, phosphorylation assays, EpoR epistasis, and ex vivo progenitor expansion assays","pmids":["14982882"],"confidence":"Medium","gaps":["Direct physical EpoR-RON interaction not shown","Differentiation block mechanism unexplained"]},{"year":2008,"claim":"Defined RON-mediated suppression of IFN-γ/STAT1 responses via SOCS1 induction, with genetic epistasis confirming the immunosuppressive output in vivo.","evidence":"Primary macrophage STAT1/CIITA assays, SOCS1 induction, and RON/IFN-γR double-knockout rescue","pmids":["18684919"],"confidence":"High","gaps":["Mechanism linking RON kinase to SOCS1 transcription not defined","Human macrophage relevance not tested"]},{"year":2008,"claim":"Revealed ligand-independent RON signaling modes (survival, spreading) mediated by Src family kinases, distinguishing them from MSP-dependent proliferation and migration.","evidence":"RON overexpression in MCF-10A cells with Src inhibition and phenotypic assays with/without MSP","pmids":["18836480"],"confidence":"Medium","gaps":["Source of MSP-independent activation not defined","Single isogenic system"]},{"year":2008,"claim":"Identified RON as a repressor of HIV-1 transcription operating at NF-κB recruitment and Pol II elongation checkpoints, an unexpected transcriptional regulatory role.","evidence":"ChIP for Pol II and elongation factors at the HIV LTR, HDAC inhibitor treatment, and nucleosome remodeling analysis","pmids":["18209063"],"confidence":"Medium","gaps":["Direct nuclear role of RON in this repression not established","Single-lab mechanism"]},{"year":2009,"claim":"Characterized a soluble antagonist isoform (RONΔ90) generated by exon skipping, demonstrating endogenous negative regulation of RON activation.","evidence":"RT-PCR, cDNA cloning, recombinant protein, and phosphorylation/migration inhibition assays","pmids":["19519771"],"confidence":"Medium","gaps":["In vivo abundance and regulation of RONΔ90 unknown","Single-lab study"]},{"year":2009,"claim":"Linked RON to tumor angiogenesis through NF-κB-driven angiogenic chemokine production in prostate cancer.","evidence":"shRNA knockdown and overexpression, NF-κB assays, chemokine ELISA, endothelial chemotaxis, and orthotopic microvessel density","pmids":["19838218"],"confidence":"Medium","gaps":["Direct RON-to-NF-κB signaling intermediates not mapped","Single-lab study"]},{"year":2010,"claim":"Mapped RON-induced arginase I expression to an AP-1/Fos promoter mechanism driving M2-like macrophage polarization and tumor growth in vivo.","evidence":"Arg1 promoter analysis, Fos ChIP at the AP-1 site, MAPK assays, and Ron(-/-) tumor models","pmids":["21810604"],"confidence":"High","gaps":["Stat6-independence mechanism not fully resolved","Human tumor-associated macrophage data limited"]},{"year":2010,"claim":"Established RON as a negative regulator of TNF-α production and shedding in alveolar macrophages via NF-κB/IκB and Adam17 control.","evidence":"Primary alveolar macrophage NF-κB assays, IκB Western, and Adam17 expression analysis","pmids":["19487969"],"confidence":"Medium","gaps":["Mechanism of Adam17 downregulation not defined","Single-lab study"]},{"year":2010,"claim":"Identified RON as an upstream activator of mutant PI3K in colon cancer, with knockdown sensitizing cells to apoptosis and reducing metastasis.","evidence":"siRNA knockdown, PI3K activity and AKT assays, apoptosis assays, and orthotopic metastasis models in PIK3CA-mutant cells","pmids":["19224914"],"confidence":"Medium","gaps":["Direct RON-PI3K coupling mechanism not defined","Single-lab study"]},{"year":2010,"claim":"Dissected opposing cell-type-specific roles of RON in liver injury using conditional knockouts, showing hepatocyte versus Kupffer cell contributions.","evidence":"Hepatocyte- and macrophage-specific Cre deletion, conditioned-media transfer, and in vivo liver injury models","pmids":["21520175"],"confidence":"High","gaps":["Molecular basis of divergent cell-type outputs not fully defined"]},{"year":2011,"claim":"Demonstrated that MET-addicted cancers transactivate RON, making RON a functional component of MET oncogene addiction and a co-target.","evidence":"MET-specific kinase inhibitors, antibody-induced MET shedding, RON shRNA, clonogenic assays, and xenografts","pmids":["21212418"],"confidence":"High","gaps":["Quantitative contribution of RON to MET-driven phenotype variable","Single-lab study"]},{"year":2011,"claim":"Established unidirectional IGF-1R-to-RON transphosphorylation driving STAT3 activation and migration in pancreatic cancer.","evidence":"MudPIT proteomics, co-IP, RON shRNA/kinase inhibitor, scratch migration, and STAT3 assays","pmids":["21565828"],"confidence":"Medium","gaps":["Structural basis of IGF-1R-RON interaction not defined","Single-lab study"]},{"year":2011,"claim":"Showed EBV LMP1 drives RON expression via NF-κB binding to the RON promoter, supporting B-cell transformation, linking viral oncogenesis to RON.","evidence":"NF-κB promoter binding, LMP1 CTAR1 mapping, shRNA, and knockdown-rescue proliferation assays","pmids":["21659546"],"confidence":"Medium","gaps":["Direct NF-κB binding site not finely mapped","Single-lab study"]},{"year":2012,"claim":"Identified a RON-plectin-ITGB4 complex whose MSP-induced disruption of hemidesmosome anchoring promotes PI3K-dependent migration.","evidence":"MudPIT, co-IP, shRNA, migration assays, and PI3K/MEK inhibition in pancreatic cancer cells","pmids":["22275185"],"confidence":"Medium","gaps":["Stoichiometry and direct contacts within the complex not defined","Single-lab study"]},{"year":2014,"claim":"Defined a PI3K→MBD4 epigenetic reprogramming pathway as a mechanistic driver of RON/MSP-mediated metastasis, with MBD4 glycosylase activity required.","evidence":"shRNA, MBD4 catalytic mutant rescue, methylation profiling, PI3K inhibition, and PDX in vivo metastasis models","pmids":["24388747"],"confidence":"High","gaps":["Mechanism by which MBD4 produces locus-specific methylation changes not resolved"]},{"year":2014,"claim":"Revealed a non-canonical nuclear function for RON under hypoxia, interacting with HIF-1α and directly activating c-JUN transcription in a kinase-dependent manner.","evidence":"Cell fractionation, co-IP, c-JUN promoter ChIP, kinase-dead mutant, reporter, and hypoxic functional assays","pmids":["24903148"],"confidence":"High","gaps":["Mechanism of RON nuclear translocation not defined","Single-lab study"]},{"year":2015,"claim":"Characterized the constitutively active P5P6 splice isoform lacking the first IPT domain, demonstrating AKT-driven transformation and tumorigenicity.","evidence":"RT-PCR, MS peptide confirmation, fractionation, kinase inhibitor, NIH3T3 transformation, and in vivo tumor formation","pmids":["26477314"],"confidence":"Medium","gaps":["Mechanism of constitutive activation upon IPT loss not defined","Single-lab study"]},{"year":2017,"claim":"Established RON signaling in osteoclast precursors as a SRC-convergent, RANKL-complementary driver of cancer-mediated bone destruction with clinical biomarker support.","evidence":"Genetic and pharmacological RON inhibition across multiple mouse osteolysis models with clinical bone-turnover biomarker data","pmids":["28123075"],"confidence":"High","gaps":["Direct osteoclast RON effectors beyond SRC convergence not mapped"]},{"year":2018,"claim":"Linked macrophage RON activation to immune checkpoint regulation, showing RON inhibition synergizes specifically with anti-CTLA-4 for tumor eradication.","evidence":"Flow cytometry of CD80/PD-L1, genetic/pharmacological RON inhibition, orthotopic tumors, and combination immunotherapy","pmids":["30228950"],"confidence":"High","gaps":["Mechanism of selectivity for anti-CTLA-4 over anti-PD-1 not resolved"]},{"year":2020,"claim":"Identified HNRNPA2B1 as the splicing factor producing the pro-EMT RONΔ165 isoform via exon 11 exclusion, connecting alternative splicing to AKT-driven EMT.","evidence":"CRISPR/Cas9 knockout, minigene splicing reporter, EMT marker analysis, and rescue overexpression","pmids":["32669614"],"confidence":"Medium","gaps":["Regulation of HNRNPA2B1 in tumors not addressed","Single-lab study"]},{"year":null,"claim":"How the diverse RON-activating inputs (MSP, MET/EGFR/IGF-1R transactivation, hypoxia-induced nuclear translocation, constitutive splice isoforms) are integrated and selectively coupled to distinct downstream programs in a given cell type remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model of input-output specificity","Structural basis of RON nuclear translocation and isoform constitutive activation undefined","Mechanism connecting RON kinase output to specific transcriptional/epigenetic effectors incompletely mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,2,8,13]},{"term_id":"GO:0001618","term_label":"virus receptor activity","supporting_discovery_ids":[0,1]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[1,5]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[20]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,1,2,30]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[20]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[30]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,8,2]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[4,13,17]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[10,11,12,26]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[20,21]}],"complexes":["MET-RON receptor complex","RON-plectin-ITGB4 complex"],"partners":["MET","EGFR","IGF1R","GAB1","PLEC","ITGB4","HIF1A","HNRNPA2B1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q04912","full_name":"Macrophage-stimulating protein receptor","aliases":["CDw136","Protein-tyrosine kinase 8","p185-Ron"],"length_aa":1400,"mass_kda":152.2,"function":"Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to MST1 ligand. Regulates many physiological processes including cell survival, migration and differentiation. Ligand binding at the cell surface induces autophosphorylation of RON on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1 or the adapter GAB1. Recruitment of these downstream effectors by RON leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. RON signaling activates the wound healing response by promoting epithelial cell migration, proliferation as well as survival at the wound site. Also plays a role in the innate immune response by regulating the migration and phagocytic activity of macrophages. Alternatively, RON can also promote signals such as cell migration and proliferation in response to growth factors other than MST1 ligand","subcellular_location":"Membrane","url":"https://www.uniprot.org/uniprotkb/Q04912/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MST1R","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MST1R","total_profiled":1310},"omim":[{"mim_id":"617075","title":"NASOPHARYNGEAL CARCINOMA, SUSCEPTIBILITY TO, 3; NPCA3","url":"https://www.omim.org/entry/617075"},{"mim_id":"615297","title":"ADAMS-OLIVER SYNDROME 4; AOS4","url":"https://www.omim.org/entry/615297"},{"mim_id":"614789","title":"EGF DOMAIN-SPECIFIC O-LINKED N-ACETYLGLUCOSAMINE TRANSFERASE; EOGT","url":"https://www.omim.org/entry/614789"},{"mim_id":"607107","title":"NASOPHARYNGEAL CARCINOMA","url":"https://www.omim.org/entry/607107"},{"mim_id":"603551","title":"HYALURONOGLUCOSAMINIDASE 2; HYAL2","url":"https://www.omim.org/entry/603551"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Cytosol","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"intestine","ntpm":18.2},{"tissue":"skin 1","ntpm":30.2},{"tissue":"stomach 1","ntpm":25.5}],"url":"https://www.proteinatlas.org/search/MST1R"},"hgnc":{"alias_symbol":["CDw136","CD136"],"prev_symbol":["RON","PTK8","SEA"]},"alphafold":{"accession":"Q04912","domains":[{"cath_id":"2.60.40.10","chopping":"567-683","consensus_level":"high","plddt":79.3396,"start":567,"end":683},{"cath_id":"2.60.40.10","chopping":"686-768","consensus_level":"high","plddt":89.6236,"start":686,"end":768},{"cath_id":"-","chopping":"880-923_930-945","consensus_level":"high","plddt":85.152,"start":880,"end":945},{"cath_id":"3.30.200.20","chopping":"1061-1164","consensus_level":"medium","plddt":83.2009,"start":1061,"end":1164},{"cath_id":"2.60.40","chopping":"772-831_844-851","consensus_level":"high","plddt":86.429,"start":772,"end":851}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q04912","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q04912-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q04912-F1-predicted_aligned_error_v6.png","plddt_mean":80.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MST1R","jax_strain_url":"https://www.jax.org/strain/search?query=MST1R"},"sequence":{"accession":"Q04912","fasta_url":"https://rest.uniprot.org/uniprotkb/Q04912.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q04912/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q04912"}},"corpus_meta":[{"pmid":"8062829","id":"PMC_8062829","title":"RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP.","date":"1994","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/8062829","citation_count":280,"is_preprint":false},{"pmid":"7939629","id":"PMC_7939629","title":"Identification of the ron gene product as the receptor for the human macrophage stimulating protein.","date":"1994","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/7939629","citation_count":243,"is_preprint":false},{"pmid":"23792360","id":"PMC_23792360","title":"MSP-RON signalling in cancer: pathogenesis and therapeutic potential.","date":"2013","source":"Nature reviews. Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23792360","citation_count":163,"is_preprint":false},{"pmid":"10871856","id":"PMC_10871856","title":"Cross-talk between the proto-oncogenes Met and Ron.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10871856","citation_count":159,"is_preprint":false},{"pmid":"18620091","id":"PMC_18620091","title":"Met-related receptor tyrosine kinase Ron in tumor growth and metastasis.","date":"2008","source":"Advances in cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18620091","citation_count":138,"is_preprint":false},{"pmid":"23275061","id":"PMC_23275061","title":"LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.","date":"2012","source":"Investigational new drugs","url":"https://pubmed.ncbi.nlm.nih.gov/23275061","citation_count":133,"is_preprint":false},{"pmid":"11486025","id":"PMC_11486025","title":"Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the beta-catenin pathway.","date":"2001","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11486025","citation_count":129,"is_preprint":false},{"pmid":"24934579","id":"PMC_24934579","title":"Plasticity and redundancy among AMA-RON pairs ensure host cell entry of Toxoplasma parasites.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/24934579","citation_count":128,"is_preprint":false},{"pmid":"21810604","id":"PMC_21810604","title":"Regulation of macrophage arginase expression and tumor growth by the Ron receptor tyrosine kinase.","date":"2011","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/21810604","citation_count":118,"is_preprint":false},{"pmid":"12807733","id":"PMC_12807733","title":"Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase.","date":"2003","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/12807733","citation_count":113,"is_preprint":false},{"pmid":"17616662","id":"PMC_17616662","title":"The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression.","date":"2007","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/17616662","citation_count":105,"is_preprint":false},{"pmid":"15827676","id":"PMC_15827676","title":"RON, a tyrosine kinase receptor involved in tumor progression and metastasis.","date":"2005","source":"Annals of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/15827676","citation_count":99,"is_preprint":false},{"pmid":"12915129","id":"PMC_12915129","title":"The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness.","date":"2003","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/12915129","citation_count":99,"is_preprint":false},{"pmid":"17889431","id":"PMC_17889431","title":"Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets.","date":"2007","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/17889431","citation_count":93,"is_preprint":false},{"pmid":"19243445","id":"PMC_19243445","title":"RNA viruses in the sea.","date":"2009","source":"FEMS microbiology reviews","url":"https://pubmed.ncbi.nlm.nih.gov/19243445","citation_count":92,"is_preprint":false},{"pmid":"15289319","id":"PMC_15289319","title":"Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression.","date":"2004","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/15289319","citation_count":88,"is_preprint":false},{"pmid":"17311308","id":"PMC_17311308","title":"Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target.","date":"2007","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17311308","citation_count":86,"is_preprint":false},{"pmid":"26578594","id":"PMC_26578594","title":"SEA: a super-enhancer archive.","date":"2015","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/26578594","citation_count":84,"is_preprint":false},{"pmid":"29724051","id":"PMC_29724051","title":"Pharmacological Potential of Sea Cucumbers.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29724051","citation_count":83,"is_preprint":false},{"pmid":"20103639","id":"PMC_20103639","title":"Silencing of RON receptor signaling promotes apoptosis and gemcitabine sensitivity in pancreatic cancers.","date":"2010","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/20103639","citation_count":83,"is_preprint":false},{"pmid":"26958906","id":"PMC_26958906","title":"Biogeography of Viruses in the Sea.","date":"2015","source":"Annual review of virology","url":"https://pubmed.ncbi.nlm.nih.gov/26958906","citation_count":82,"is_preprint":false},{"pmid":"26868354","id":"PMC_26868354","title":"Rare cancers: a sea of opportunity.","date":"2016","source":"The Lancet. Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/26868354","citation_count":82,"is_preprint":false},{"pmid":"12472665","id":"PMC_12472665","title":"Macrophage-stimulating protein and RON receptor tyrosine kinase: potential regulators of macrophage inflammatory activities.","date":"2002","source":"Scandinavian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12472665","citation_count":70,"is_preprint":false},{"pmid":"26951679","id":"PMC_26951679","title":"Whole-exome sequencing identifies MST1R as a genetic susceptibility gene in nasopharyngeal carcinoma.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/26951679","citation_count":70,"is_preprint":false},{"pmid":"11593422","id":"PMC_11593422","title":"Point mutations and overexpression of Ron induce transformation, tumor formation, and metastasis.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11593422","citation_count":68,"is_preprint":false},{"pmid":"15651637","id":"PMC_15651637","title":"Compatible and counteracting solutes: protecting cells from the Dead Sea to the deep sea.","date":"2004","source":"Science progress","url":"https://pubmed.ncbi.nlm.nih.gov/15651637","citation_count":67,"is_preprint":false},{"pmid":"15735014","id":"PMC_15735014","title":"Ron receptor signaling augments mammary tumor formation and metastasis in a murine model of breast cancer.","date":"2005","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/15735014","citation_count":67,"is_preprint":false},{"pmid":"19199866","id":"PMC_19199866","title":"From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer.","date":"2009","source":"Anti-cancer agents in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19199866","citation_count":66,"is_preprint":false},{"pmid":"19224914","id":"PMC_19224914","title":"Knockdown of Ron kinase inhibits mutant phosphatidylinositol 3-kinase and reduces metastasis in human colon carcinoma.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19224914","citation_count":65,"is_preprint":false},{"pmid":"25042930","id":"PMC_25042930","title":"Vocal learning in seals, sea lions, and walruses.","date":"2014","source":"Current opinion in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/25042930","citation_count":63,"is_preprint":false},{"pmid":"21212418","id":"PMC_21212418","title":"Ron kinase transphosphorylation sustains MET oncogene addiction.","date":"2011","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/21212418","citation_count":63,"is_preprint":false},{"pmid":"20959493","id":"PMC_20959493","title":"Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas.","date":"2010","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/20959493","citation_count":62,"is_preprint":false},{"pmid":"20689759","id":"PMC_20689759","title":"Ron receptor tyrosine kinase activation confers resistance to tamoxifen in breast cancer cell lines.","date":"2010","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/20689759","citation_count":60,"is_preprint":false},{"pmid":"15378025","id":"PMC_15378025","title":"RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells.","date":"2004","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15378025","citation_count":60,"is_preprint":false},{"pmid":"14499632","id":"PMC_14499632","title":"Cross-talk between the receptor tyrosine kinases Ron and epidermal growth factor receptor.","date":"2003","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/14499632","citation_count":58,"is_preprint":false},{"pmid":"12570659","id":"PMC_12570659","title":"Oncogenic signaling pathways activated by RON receptor tyrosine kinase.","date":"2003","source":"Current cancer drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/12570659","citation_count":57,"is_preprint":false},{"pmid":"28123075","id":"PMC_28123075","title":"RON kinase: A target for treatment of cancer-induced bone destruction and osteoporosis.","date":"2017","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28123075","citation_count":55,"is_preprint":false},{"pmid":"19838218","id":"PMC_19838218","title":"The Ron receptor tyrosine kinase positively regulates angiogenic chemokine production in prostate cancer cells.","date":"2009","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/19838218","citation_count":54,"is_preprint":false},{"pmid":"20545605","id":"PMC_20545605","title":"The macrophage stimulating protein/Ron pathway as a potential therapeutic target to impede multiple mechanisms involved in breast cancer progression.","date":"2010","source":"Current drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/20545605","citation_count":51,"is_preprint":false},{"pmid":"21520175","id":"PMC_21520175","title":"Ron receptor regulates Kupffer cell-dependent cytokine production and hepatocyte survival following endotoxin exposure in mice.","date":"2011","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/21520175","citation_count":50,"is_preprint":false},{"pmid":"25784650","id":"PMC_25784650","title":"Roles of c-Met and RON kinases in tumor progression and their potential as therapeutic targets.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25784650","citation_count":49,"is_preprint":false},{"pmid":"23328584","id":"PMC_23328584","title":"Myeloid-specific expression of Ron receptor kinase promotes prostate tumor growth.","date":"2013","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/23328584","citation_count":47,"is_preprint":false},{"pmid":"18684919","id":"PMC_18684919","title":"The RON receptor tyrosine kinase regulates IFN-gamma production and responses in innate immunity.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18684919","citation_count":45,"is_preprint":false},{"pmid":"22275185","id":"PMC_22275185","title":"The RON-receptor regulates pancreatic cancer cell migration through phosphorylation-dependent breakdown of the hemidesmosome.","date":"2012","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22275185","citation_count":44,"is_preprint":false},{"pmid":"10080538","id":"PMC_10080538","title":"Kinases involved in MSP/RON signaling.","date":"1999","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/10080538","citation_count":43,"is_preprint":false},{"pmid":"24388747","id":"PMC_24388747","title":"The RON receptor tyrosine kinase promotes metastasis by triggering MBD4-dependent DNA methylation reprogramming.","date":"2014","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/24388747","citation_count":43,"is_preprint":false},{"pmid":"19519771","id":"PMC_19519771","title":"RON receptor tyrosine kinase in human gliomas: expression, function, and identification of a novel soluble splice variant.","date":"2009","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19519771","citation_count":43,"is_preprint":false},{"pmid":"19040718","id":"PMC_19040718","title":"Expression of the RON receptor tyrosine kinase and its association with gastric carcinoma versus normal gastric tissues.","date":"2008","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19040718","citation_count":42,"is_preprint":false},{"pmid":"20694025","id":"PMC_20694025","title":"Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy.","date":"2010","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/20694025","citation_count":41,"is_preprint":false},{"pmid":"19487969","id":"PMC_19487969","title":"Ron receptor tyrosine kinase negatively regulates TNFalpha production in alveolar macrophages by inhibiting NF-kappaB activity and Adam17 production.","date":"2010","source":"Shock (Augusta, Ga.)","url":"https://pubmed.ncbi.nlm.nih.gov/19487969","citation_count":41,"is_preprint":false},{"pmid":"18836480","id":"PMC_18836480","title":"The RON receptor tyrosine kinase promotes MSP-independent cell spreading and survival in breast epithelial cells.","date":"2008","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/18836480","citation_count":39,"is_preprint":false},{"pmid":"21565828","id":"PMC_21565828","title":"IGF1-R signals through the RON receptor to mediate pancreatic cancer cell migration.","date":"2011","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/21565828","citation_count":39,"is_preprint":false},{"pmid":"17661719","id":"PMC_17661719","title":"Ron-receptor tyrosine kinase in tumorigenesis and metastasis.","date":"2007","source":"Future oncology (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/17661719","citation_count":38,"is_preprint":false},{"pmid":"27533251","id":"PMC_27533251","title":"FOXC1 promotes melanoma by activating MST1R/PI3K/AKT.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27533251","citation_count":38,"is_preprint":false},{"pmid":"16723080","id":"PMC_16723080","title":"Oncogenesis of RON receptor tyrosine kinase: a molecular target for malignant epithelial cancers.","date":"2006","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/16723080","citation_count":38,"is_preprint":false},{"pmid":"14597639","id":"PMC_14597639","title":"The soluble sema domain of the RON receptor inhibits macrophage-stimulating protein-induced receptor activation.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14597639","citation_count":38,"is_preprint":false},{"pmid":"14982882","id":"PMC_14982882","title":"Tyrosine kinase receptor RON functions downstream of the erythropoietin receptor to induce expansion of erythroid progenitors.","date":"2004","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/14982882","citation_count":36,"is_preprint":false},{"pmid":"35731833","id":"PMC_35731833","title":"The AMA1-RON complex drives Plasmodium sporozoite invasion in the mosquito and mammalian hosts.","date":"2022","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/35731833","citation_count":36,"is_preprint":false},{"pmid":"12395314","id":"PMC_12395314","title":"Deletion of the Ron receptor tyrosine kinase domain in mice provides protection from endotoxin-induced acute liver failure.","date":"2002","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/12395314","citation_count":36,"is_preprint":false},{"pmid":"29187708","id":"PMC_29187708","title":"Library Construction from Subnanogram DNA for Pelagic Sea Water and Deep-Sea Sediments.","date":"2017","source":"Microbes and environments","url":"https://pubmed.ncbi.nlm.nih.gov/29187708","citation_count":33,"is_preprint":false},{"pmid":"17070309","id":"PMC_17070309","title":"Collaboration of RON and epidermal growth factor receptor in human bladder carcinogenesis.","date":"2006","source":"The Journal of urology","url":"https://pubmed.ncbi.nlm.nih.gov/17070309","citation_count":33,"is_preprint":false},{"pmid":"11751209","id":"PMC_11751209","title":"The role of the receptor tyrosine kinase Ron in nickel-induced acute lung injury.","date":"2002","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11751209","citation_count":33,"is_preprint":false},{"pmid":"22585712","id":"PMC_22585712","title":"Differential expression of RON in small and non-small cell lung cancers.","date":"2012","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22585712","citation_count":32,"is_preprint":false},{"pmid":"18593918","id":"PMC_18593918","title":"Curcumin blocks RON tyrosine kinase-mediated invasion of breast carcinoma cells.","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18593918","citation_count":32,"is_preprint":false},{"pmid":"26477314","id":"PMC_26477314","title":"A novel protein isoform of the RON tyrosine kinase receptor transforms human pancreatic duct epithelial cells.","date":"2015","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/26477314","citation_count":32,"is_preprint":false},{"pmid":"15252311","id":"PMC_15252311","title":"Expression of RON Proto-oncogene in Renal Oncocytoma and Chromophobe Renal Cell Carcinoma.","date":"2004","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15252311","citation_count":32,"is_preprint":false},{"pmid":"33117355","id":"PMC_33117355","title":"MSP-RON Pathway: Potential Regulator of Inflammation and Innate Immunity.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33117355","citation_count":31,"is_preprint":false},{"pmid":"22834780","id":"PMC_22834780","title":"Ron receptor tyrosine kinase signaling as a therapeutic target.","date":"2012","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/22834780","citation_count":31,"is_preprint":false},{"pmid":"32669614","id":"PMC_32669614","title":"The HNRNPA2B1-MST1R-Akt axis contributes to epithelial-to-mesenchymal transition in head and neck cancer.","date":"2020","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/32669614","citation_count":31,"is_preprint":false},{"pmid":"30967626","id":"PMC_30967626","title":"MST1R kinase accelerates pancreatic cancer progression via effects on both epithelial cells and macrophages.","date":"2019","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/30967626","citation_count":30,"is_preprint":false},{"pmid":"9467940","id":"PMC_9467940","title":"Characterization of the mouse Ron/Stk receptor tyrosine kinase gene.","date":"1998","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9467940","citation_count":30,"is_preprint":false},{"pmid":"30228950","id":"PMC_30228950","title":"Inhibition of RON kinase potentiates anti-CTLA-4 immunotherapy to shrink breast tumors and prevent metastatic outgrowth.","date":"2018","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/30228950","citation_count":30,"is_preprint":false},{"pmid":"25641694","id":"PMC_25641694","title":"Juvenile skeletogenesis in anciently diverged sea urchin clades.","date":"2015","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/25641694","citation_count":30,"is_preprint":false},{"pmid":"25400637","id":"PMC_25400637","title":"Regulation of Macrophage Polarization by RON Receptor Tyrosine Kinase Signaling.","date":"2014","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25400637","citation_count":28,"is_preprint":false},{"pmid":"24903148","id":"PMC_24903148","title":"Hypoxia promotes nuclear translocation and transcriptional function in the oncogenic tyrosine kinase RON.","date":"2014","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/24903148","citation_count":28,"is_preprint":false},{"pmid":"35454943","id":"PMC_35454943","title":"The MST1R/RON Tyrosine Kinase in Cancer: Oncogenic Functions and Therapeutic Strategies.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/35454943","citation_count":27,"is_preprint":false},{"pmid":"8103724","id":"PMC_8103724","title":"Antitumor and antimicrobial glycoproteins from sea hares.","date":"1993","source":"Comparative biochemistry and physiology. C, Comparative pharmacology and toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/8103724","citation_count":27,"is_preprint":false},{"pmid":"11332718","id":"PMC_11332718","title":"Cross-talk between RON receptor tyrosine kinase and other transmembrane receptors.","date":"2001","source":"Histology and histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/11332718","citation_count":26,"is_preprint":false},{"pmid":"18200509","id":"PMC_18200509","title":"Two-stage candidate gene study of chromosome 3p demonstrates an association between nonsynonymous variants in the MST1R gene and Crohn's disease.","date":"2008","source":"Inflammatory bowel diseases","url":"https://pubmed.ncbi.nlm.nih.gov/18200509","citation_count":26,"is_preprint":false},{"pmid":"32793180","id":"PMC_32793180","title":"Coronaviruses in the Sea.","date":"2020","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/32793180","citation_count":25,"is_preprint":false},{"pmid":"28440432","id":"PMC_28440432","title":"RON and c-Met facilitate metastasis through the ERK signaling pathway in prostate cancer cells.","date":"2017","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/28440432","citation_count":25,"is_preprint":false},{"pmid":"20098613","id":"PMC_20098613","title":"Terpenyl-purines from the sea.","date":"2009","source":"Marine drugs","url":"https://pubmed.ncbi.nlm.nih.gov/20098613","citation_count":25,"is_preprint":false},{"pmid":"22235915","id":"PMC_22235915","title":"Met interacts with EGFR and Ron in canine osteosarcoma.","date":"2011","source":"Veterinary and comparative oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22235915","citation_count":25,"is_preprint":false},{"pmid":"27323855","id":"PMC_27323855","title":"Characterization of RON protein isoforms in pancreatic cancer: implications for biology and therapeutics.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27323855","citation_count":25,"is_preprint":false},{"pmid":"24086167","id":"PMC_24086167","title":"Pathogenesis of RON receptor tyrosine kinase in cancer cells: activation mechanism, functional crosstalk, and signaling addiction.","date":"2013","source":"Journal of biomedical research","url":"https://pubmed.ncbi.nlm.nih.gov/24086167","citation_count":24,"is_preprint":false},{"pmid":"33257837","id":"PMC_33257837","title":"RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer.","date":"2020","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33257837","citation_count":24,"is_preprint":false},{"pmid":"21659546","id":"PMC_21659546","title":"Requirement for LMP1-induced RON receptor tyrosine kinase in Epstein-Barr virus-mediated B-cell proliferation.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21659546","citation_count":24,"is_preprint":false},{"pmid":"30275241","id":"PMC_30275241","title":"RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE.","date":"2018","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/30275241","citation_count":24,"is_preprint":false},{"pmid":"24518495","id":"PMC_24518495","title":"The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapies.","date":"2014","source":"Pancreas","url":"https://pubmed.ncbi.nlm.nih.gov/24518495","citation_count":23,"is_preprint":false},{"pmid":"21805525","id":"PMC_21805525","title":"Laboratory on sea urchin fertilization.","date":"2011","source":"Molecular reproduction and development","url":"https://pubmed.ncbi.nlm.nih.gov/21805525","citation_count":22,"is_preprint":false},{"pmid":"28057847","id":"PMC_28057847","title":"RON Signaling Is a Key Mediator of Tumor Progression in Many Human Cancers.","date":"2017","source":"Cold Spring Harbor symposia on quantitative biology","url":"https://pubmed.ncbi.nlm.nih.gov/28057847","citation_count":22,"is_preprint":false},{"pmid":"19576199","id":"PMC_19576199","title":"The Ron receptor tyrosine kinase negatively regulates mammary gland branching morphogenesis.","date":"2009","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/19576199","citation_count":21,"is_preprint":false},{"pmid":"18209063","id":"PMC_18209063","title":"The receptor tyrosine kinase RON represses HIV-1 transcription by targeting RNA polymerase II processivity.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18209063","citation_count":21,"is_preprint":false},{"pmid":"23922886","id":"PMC_23922886","title":"Ron knockdown and Ron monoclonal antibody IMC-RON8 sensitize pancreatic cancer to histone deacetylase inhibitors (HDACi).","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23922886","citation_count":21,"is_preprint":false},{"pmid":"20358644","id":"PMC_20358644","title":"The RON tyrosine kinase receptor regulates vascular endothelial growth factor production in pancreatic cancer cells.","date":"2010","source":"Pancreas","url":"https://pubmed.ncbi.nlm.nih.gov/20358644","citation_count":21,"is_preprint":false},{"pmid":"15531916","id":"PMC_15531916","title":"Ron tyrosine kinase receptor regulates papilloma growth and malignant conversion in a murine model of skin carcinogenesis.","date":"2005","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15531916","citation_count":21,"is_preprint":false},{"pmid":"17588532","id":"PMC_17588532","title":"Human RON receptor tyrosine kinase induces complete epithelial-to-mesenchymal transition but causes cellular senescence.","date":"2007","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/17588532","citation_count":20,"is_preprint":false},{"pmid":"9890710","id":"PMC_9890710","title":"Characterization of two monoclonal antibodies against the RON tyrosine kinase receptor.","date":"1998","source":"Hybridoma","url":"https://pubmed.ncbi.nlm.nih.gov/9890710","citation_count":19,"is_preprint":false},{"pmid":"11818458","id":"PMC_11818458","title":"Activation of the RON receptor tyrosine kinase protects murine macrophages from apoptotic death induced by bacterial lipopolysaccharide.","date":"2002","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/11818458","citation_count":19,"is_preprint":false},{"pmid":"31959288","id":"PMC_31959288","title":"Gastrulation in the sea urchin.","date":"2019","source":"Current topics in developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/31959288","citation_count":18,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":45715,"output_tokens":8709,"usd":0.13389,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18701,"output_tokens":7028,"usd":0.134603,"stage2_stop_reason":"end_turn"},"total_usd":0.268493,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"RON is a heterodimeric receptor tyrosine kinase: the single-chain precursor is glycosylated, cleaved into a 185 kDa disulfide-linked heterodimer (35 kDa alpha + 150 kDa beta chains), and the beta-chain displays intrinsic tyrosine kinase activity in vitro. MSP (macrophage stimulating protein), a HGF homologue, specifically activates RON by inducing tyrosine phosphorylation, leading to DNA synthesis in epithelial cells. HGF does not activate RON, nor does MSP activate the HGF receptor.\",\n      \"method\": \"Immunoprecipitation, in vitro kinase assay, ligand stimulation assays, biochemical cross-reactivity experiments\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase assay with immunoprecipitation, confirmed ligand specificity with reciprocal negative controls, replicated in a concurrent independent study (PMID:7939629)\",\n      \"pmids\": [\"8062829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"The RON gene product is confirmed as the specific cell-surface receptor for MSP: 125I-MSP cross-links to a 220 kDa complex (MSP + RON beta chain) in RON-transfected MDCK cells, MSP binding is competed by unlabeled MSP but not by HGF-SF, MSP induces phosphorylation of the RON beta chain, and triggers cell migration.\",\n      \"method\": \"Radioligand binding, chemical cross-linking, immunoprecipitation, cell migration assay\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct ligand-receptor binding with cross-linking and immunoprecipitation, negative control with HGF, replicated by concurrent independent study (PMID:8062829)\",\n      \"pmids\": [\"7939629\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"MET and RON receptors form non-covalent complexes on the cell surface and undergo direct transphosphorylation: ligand-activated MET transphosphorylates RON (and vice versa) at both kinase-activating tyrosines (Y1238/Y1239 in RON) and signal transducer docking sites (Y1353/Y1360 in RON). This cross-talk is restricted to the scatter factor receptor subfamily and does not occur with ErbB1, ErbB2, or TrkA. A kinase-inactive RON acts as a dominant negative suppressor of oncogenic MET mutants.\",\n      \"method\": \"Kinase-inactive mutant receptor expression, cell-surface cross-linking, phosphorylation site mapping, focus-formation transformation assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution with defined kinase-dead mutants, phosphorylation site specificity mapped, negative controls with unrelated RTKs, dominant negative rescue experiment\",\n      \"pmids\": [\"10871856\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Oncogenic mutants of RON cause tyrosine phosphorylation and accumulation of beta-catenin, constitutive activation of Tcf transcription factor, and increased c-myc and cyclin D1 expression. Interference with the beta-catenin pathway reduces the transforming potential of mutant RON, establishing beta-catenin/Tcf as a downstream oncogenic signaling pathway of RON.\",\n      \"method\": \"Transfection of oncogenic RON mutants, beta-catenin tyrosine phosphorylation assay, Tcf luciferase reporter, Western blot, dominant-negative pathway interference\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (phosphorylation, reporter assay, protein level, dominant negative rescue), confirmed in multiple cell lines\",\n      \"pmids\": [\"11486025\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Point mutations in RON analogous to oncogenic MET mutations (hereditary papillary renal carcinoma) result in constitutive RON phosphorylation, cellular transformation in NIH3T3 cells, in vivo tumor formation, and lung metastasis in experimental metastasis models.\",\n      \"method\": \"Site-directed mutagenesis, NIH3T3 transformation assay, in vivo tumor formation, experimental metastasis model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — mutagenesis with in vitro and in vivo functional validation across multiple mutants\",\n      \"pmids\": [\"11593422\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The sema domain of RON participates in MSP ligand binding by the full-length receptor. A soluble secreted sema domain fragment (ron-sema) exerts a dominant negative effect on MSP-induced RON activation, inhibiting downstream signaling pathways and MSP-dependent cellular responses including proliferation.\",\n      \"method\": \"Soluble sema domain expression, dominant-negative phosphorylation assay, cell proliferation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional domain mapped by dominant-negative secreted fragment with signaling and cellular readouts, single lab\",\n      \"pmids\": [\"14597639\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"RON and EGFR physically associate (co-immunoprecipitate) in NIH3T3 cells; ligand stimulation of either RON (with HGFL) or EGFR (with EGF) induces phosphorylation of both receptors. Dominant-negative EGFR suppresses RON-induced cell scatter, and dominant-negative RON suppresses EGFR-induced focus formation, establishing functional cross-talk between these heterologous RTKs.\",\n      \"method\": \"Co-immunoprecipitation, Western phosphorylation assay, dominant-negative co-transfection, cell scatter assay, focus formation assay\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP plus dominant-negative functional rescue, single lab\",\n      \"pmids\": [\"14499632\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"A truncated RON variant (sf-RON) lacking most of the extracellular domain but retaining the transmembrane and intracellular domains is constitutively phosphorylated and has strong intrinsic tyrosine kinase activity. Epithelial cells transduced with sf-RON lose E-cadherin expression through a dominant transcriptional repression pathway mediated by the transcription factor SLUG, inducing EMT and an aggressive phenotype.\",\n      \"method\": \"Retroviral transduction, Western blot, kinase assay, morphological analysis, anchorage-independent growth, SLUG expression analysis\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — constitutive activity confirmed biochemically, EMT mechanism traced to SLUG, single lab with multiple phenotypic readouts\",\n      \"pmids\": [\"15289319\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"MSP/RON signaling activates multiple distinct intracellular kinase pathways: FAK, c-Src, AKT, MAPK, and JNK are rapidly activated by MSP. MAPK and c-Src operate in one cascade (MAPK downstream of c-Src) mediating cell proliferation; FAK mediates proliferation via a separate pathway; PI3K/AKT mediates anti-apoptotic effects; PI3K regulates adhesion and motility via AKT-independent downstream components.\",\n      \"method\": \"In vitro kinase assays, pharmacological inhibition, dominant-negative expression, MSP stimulation time-course\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple kinase pathways mapped with inhibitors and dominant negatives, single lab\",\n      \"pmids\": [\"10080538\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"RON functions downstream of the erythropoietin receptor (EpoR) in erythroid progenitor expansion: Gab1 is constitutively associated with RON; EPO activates RON, which phosphorylates Gab1, MAPK, and PKB/AKT (but not STAT5). RON activation is sufficient to replace EPO in progenitor expansion but not in differentiation.\",\n      \"method\": \"Co-immunoprecipitation, phosphorylation assays, EPO receptor signaling epistasis, ex vivo erythroid progenitor expansion assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — constitutive RON-Gab1 association by co-IP, functional epistasis (RON downstream of EpoR) with defined readouts, single lab\",\n      \"pmids\": [\"14982882\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"RON activation by MSP inhibits IFN-γ-induced STAT1 phosphorylation and CIITA expression in macrophages, reducing surface MHC class II levels. MSP/RON signaling induces suppressor of cytokine signaling 1 (SOCS1), providing a mechanistic explanation for RON-mediated inhibition of IFN-γ responses. In RON(-/-) mice, the enhanced susceptibility to LPS challenge is dependent on IFN-γ signaling (shown by RON/IFN-γR double knockout rescue).\",\n      \"method\": \"Primary macrophage stimulation, STAT1 phosphorylation assay, CIITA expression analysis, SOCS1 induction, genetic epistasis with double-knockout mice\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — biochemical mechanism (SOCS1 induction, STAT1 inhibition) plus genetic epistasis with double-knockout, multiple orthogonal methods\",\n      \"pmids\": [\"18684919\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"RON activation by MSP induces arginase I (Arg1) expression in macrophages through an AP-1 site located 433 bp upstream of the Arg1 transcription start site, via MAPK activation, Fos upregulation, and Fos binding to the AP-1 site. This mechanism is Stat6-independent. In vivo, Arg1 expression in tumor-associated macrophages is reduced in Ron(-/-) mice and is associated with reduced syngeneic tumor growth.\",\n      \"method\": \"Arg1 promoter analysis, chromatin immunoprecipitation (Fos binding to AP-1), MAPK activation assay, Ron(-/-) mouse model, tumor growth assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — promoter mechanism mapped by ChIP and AP-1 site identification, in vivo validation with knockout mice, multiple orthogonal methods\",\n      \"pmids\": [\"21810604\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"RON negatively regulates TNF-alpha production in alveolar macrophages by inhibiting NF-κB activation and increasing IκB levels following LPS challenge. RON activation also negatively regulates Adam17 (the metalloprotease responsible for TNF-alpha processing), establishing RON as a regulator of both TNF-alpha production and shedding.\",\n      \"method\": \"Primary alveolar macrophage stimulation, NF-κB activity assay, IκB Western blot, Adam17 expression analysis, MH-S alveolar macrophage cell line\",\n      \"journal\": \"Shock\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple signaling nodes (NF-κB, IκB, Adam17) examined in primary cells and cell line, single lab\",\n      \"pmids\": [\"19487969\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"In MET-amplified and MET-addicted cancer cells, activated MET specifically transphosphorylates RON kinase. RON phosphorylation is suppressed by MET-specific kinase inhibitors (PHA-665752 or JNJ-38877605) or by antibody-induced shedding of cell-surface MET. shRNA silencing of RON in MET-addicted cells decreases proliferation, clonogenic activity in vitro, and tumorigenicity in vivo, establishing RON transactivation as a component of MET oncogene addiction.\",\n      \"method\": \"Phosphorylation assays, MET-specific kinase inhibitors, antibody-induced MET shedding, shRNA knockdown, in vitro clonogenic assay, in vivo xenograft\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple pharmacological and genetic approaches to confirm MET→RON transphosphorylation, in vitro and in vivo functional validation, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"21212418\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"RON signaling in macrophages suppresses LPS-induced TNF-α production while in hepatocytes it inhibits cell survival. Conditional Ron deletion studies show: Ron loss in hepatocytes leads to less liver damage and increased survival, whereas Ron loss in macrophages leads to increased cytokine production that is toxic to hepatocytes. TK(-/-) Kupffer cells produce more TNF-α after LPS, and conditioned media from these cells is more hepatotoxic.\",\n      \"method\": \"Cell-type-specific conditional Ron deletion (hepatocyte- and macrophage-specific Cre), purified primary cell cultures, conditioned media transfer assay, in vivo liver injury model\",\n      \"journal\": \"Hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific conditional knockouts with orthogonal in vitro and in vivo validation, mechanistic dissection of Kupffer cell vs. hepatocyte contributions\",\n      \"pmids\": [\"21520175\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"RON interacts with plectin and integrin-β4 (ITGB4) in pancreatic cancer cells. Upon MSP stimulation, RON binds to plectin and ITGB4, disrupting the plectin-ITGB4 interaction that normally anchors hemidesmosomes to the extracellular matrix. This disruption enhances cell migration in a manner dependent on RON and PI3K activity, but not MEK.\",\n      \"method\": \"Multidimensional protein identification analysis (MudPIT), co-immunoprecipitation, shRNA knockdown, cell migration assay, pharmacological PI3K/MEK inhibition\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — novel RON-plectin-ITGB4 complex identified by MS and confirmed by co-IP, functional validation by shRNA and inhibitors, single lab\",\n      \"pmids\": [\"22275185\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"IGF-1R physically interacts with RON in pancreatic cancer cells. IGF-1 induces rapid phosphorylation of RON, but RON signaling does not activate IGF-1R (unidirectional signaling). IGF-1-induced pancreatic cancer cell migration is RON-dependent: shRNA knockdown of RON or RON kinase inhibitor abrogates IGF-1-induced wound closure. In pancreatic cancer cells, IGF-1 activates STAT3 in a RON-dependent manner.\",\n      \"method\": \"MudPIT proteomics, co-immunoprecipitation, shRNA knockdown, kinase inhibitor, scratch wound migration assay, STAT3 phosphorylation assay\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — interaction confirmed by MS and co-IP, directional signaling established, functional migration assay with genetic and pharmacological RON inhibition, single lab\",\n      \"pmids\": [\"21565828\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"RON/MSP signaling promotes breast cancer metastasis through an epigenetic reprogramming pathway: via PI3K signaling, RON/MSP induces expression of the DNA glycosylase MBD4, which drives aberrant DNA methylation at specific loci misregulating a defined gene set. MBD4 glycosylase catalytic activity is required for RON/MSP-driven metastasis. Knockdown of MBD4 reverses methylation and blocks metastasis.\",\n      \"method\": \"shRNA knockdown, MBD4 catalytic mutant rescue, methylation profiling, PI3K inhibition, in vivo metastasis assay, patient-derived xenograft pharmacological RON inhibition\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — catalytic mutant rescue establishes mechanistic requirement for MBD4 enzymatic activity, multiple orthogonal methods including in vivo PDX model, methylation profiling links signaling to epigenetic output\",\n      \"pmids\": [\"24388747\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"A novel soluble RON splice variant (RONDelta90), generated by skipping exon 6 causing a frameshift and premature termination in exon 7, is secreted as a truncated soluble protein. RONDelta90 inhibits MSP-induced phosphorylation of full-length cellular RON, attenuates basal RON activation, and inhibits MSP-induced glioma cell migration and random motility, functioning as an endogenous antagonist.\",\n      \"method\": \"RT-PCR, cDNA cloning, recombinant protein expression and purification, RON phosphorylation inhibition assay, cell migration assay\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — novel splice variant cloned and expressed recombinantly, functional antagonism demonstrated with biochemical and cell migration assays, single lab\",\n      \"pmids\": [\"19519771\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"RON promotes MSP-independent cell survival, increased cell spreading, and enhanced migration in response to other growth factors when expressed in MCF-10A breast epithelial cells. Both MSP-dependent and MSP-independent RON signaling are mediated in part by Src family kinases. RON-mediated proliferation and directional migration require MSP, but survival and spreading do not.\",\n      \"method\": \"RON overexpression in MCF-10A cells, Src family kinase inhibition, cell survival assay, spreading assay, migration assay with/without MSP\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ligand-dependent vs. independent signaling modes dissected in isogenic system with pharmacological inhibition, single lab\",\n      \"pmids\": [\"18836480\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Under hypoxic conditions, RON translocates to the nucleus of cancer cells. Nuclear RON interacts with HIF-1α in a manner dependent on RON tyrosine kinase activity, binds the c-JUN promoter, and activates c-JUN transcription. Nuclear RON plays a more important role than HIF-1α in c-JUN promoter activation, promoting cancer cell survival, proliferation, and tumorigenicity under hypoxia.\",\n      \"method\": \"Cell fractionation, co-immunoprecipitation of nuclear RON with HIF-1α, chromatin immunoprecipitation at c-JUN promoter, kinase-dead mutant, reporter assay, functional proliferation/survival assays under hypoxia\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — nuclear localization confirmed by fractionation, HIF-1α interaction by co-IP, promoter binding by ChIP, kinase-dependence by kinase-dead mutant, multiple functional readouts\",\n      \"pmids\": [\"24903148\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"RON represses HIV-1 transcription at multiple checkpoints: RON expression decreases NF-κB and RNA Pol II binding to the HIV LTR, reduces RNA Pol II processivity at sequences downstream of the transcription start site, and increases binding of negative elongation factors NELF, Spt5, and Pcf11. RON-mediated repression is sensitive to HDAC inhibition and is associated with nucleosome remodeling.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP) for transcription factors and Pol II at HIV LTR, elongation factor binding assay, HDAC inhibitor treatment, nucleosome remodeling analysis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-based mechanism mapping at multiple transcriptional checkpoints, single lab\",\n      \"pmids\": [\"18209063\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"RON activation by MSP inhibits LPS-induced apoptosis of macrophages by suppressing nitric oxide production and p53 accumulation. The anti-apoptotic effect of RON requires PI3K activity, as demonstrated by wortmannin inhibition and dominant-negative PI3K p85 subunit expression.\",\n      \"method\": \"Primary peritoneal macrophage assay, NO measurement, p53 Western blot, wortmannin pharmacological inhibition, dominant-negative PI3K p85 expression, apoptosis assay\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanism traced to PI3K/p53/NO axis using both pharmacological and dominant-negative genetic approaches, single lab\",\n      \"pmids\": [\"11818458\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"EBV latent membrane protein 1 (LMP1) enhances RON expression through its C-terminal activation region-1 (CTAR1) by promoting NF-κB binding to the RON promoter. RON is expressed in EBV-transformed lymphoblastoid cell lines (LCLs) but not primary B cells; RON knockdown decreases LCL proliferation, and RON re-expression compensates for growth inhibition caused by LMP1 knockdown.\",\n      \"method\": \"NF-κB binding to RON promoter assay, LMP1 CTAR1 domain mapping, shRNA knockdown, rescue overexpression, proliferation assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter mechanism mapped, functional epistasis between LMP1 and RON established by knockdown-rescue, single lab\",\n      \"pmids\": [\"21659546\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"The splicing factor HNRNPA2B1 mediates exclusion of cassette exon 11 from MST1R pre-mRNA, producing the RON∆165 isoform. CRISPR/Cas9 knockout of HNRNPA2B1 reduces RON∆165 production (confirmed by minigene assay), decreases Akt/PKB signaling, upregulates E-cadherin and downregulates vimentin, reducing EMT. HNRNPA2B1 overexpression in KO cells rescues RON∆165 expression and restores Akt activation and EMT.\",\n      \"method\": \"CRISPR/Cas9 knockout, minigene splicing reporter assay, Western blot, EMT marker analysis, rescue overexpression\",\n      \"journal\": \"Laboratory investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — splice mechanism validated by minigene, CRISPR KO with functional rescue, multiple downstream markers, single lab\",\n      \"pmids\": [\"32669614\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"MSP signals through RON expressed on osteoclast precursors to activate osteoclasts by a pathway complementary to RANKL signaling and converging on SRC kinase. Genetic or pharmacological inhibition of RON kinase blocks cancer-mediated bone destruction and osteoporosis in multiple mouse models. Clinical trial data show that a RON kinase inhibitor (BMS-777607/ASLAN002) alters markers of bone turnover in cancer patients.\",\n      \"method\": \"Genetic RON deletion, pharmacological RON inhibition, multiple mouse osteolysis models, SRC pathway analysis, clinical biomarker analysis\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple mouse model systems with both genetic and pharmacological inhibition, SRC convergence identified, clinical biomarker validation in human trial\",\n      \"pmids\": [\"28123075\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"RON activation by MSP in macrophages upregulates surface levels of CD80 and PD-L1 (ligands for CTLA-4 and PD-1 on T cells). Genetic deletion or pharmacological inhibition of RON combined with anti-CTLA-4 (but not anti-PD-1) results in complete tumor eradication in ~46% of animals, associated with higher T-cell activation and tumor-infiltrating lymphocytes.\",\n      \"method\": \"Flow cytometry for CD80/PD-L1 surface expression, genetic Ron deletion, pharmacological inhibition, orthotopic tumor transplantation, combination immunotherapy study, T-cell activation markers\",\n      \"journal\": \"Oncoimmunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mechanism (CD80/PD-L1 upregulation) linked to immune outcome, genetic and pharmacological RON inhibition, in vivo therapeutic validation, selectivity for anti-CTLA-4 over anti-PD-1 established\",\n      \"pmids\": [\"30228950\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"RON knockdown in HCT116 colon cancer cells (heterozygous for PIK3CA H1047R gain-of-function mutation) reduces mutant PI3K activity and AKT phosphorylation, sensitizes cells to growth factor deprivation-induced apoptosis, and significantly reduces lung metastasis in orthotopic models. This establishes RON as an upstream activator of mutant PI3K in colon cancer.\",\n      \"method\": \"siRNA knockdown, PI3K activity assay, AKT phosphorylation, caspase-3/DNA fragmentation apoptosis assay, orthotopic metastasis model\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RON-PI3K signaling link demonstrated biochemically and functionally in vitro and in vivo, single lab\",\n      \"pmids\": [\"19224914\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"MSP stimulation of pancreatic cancer cells results in increased phosphorylation of MAPK and AKT via RON, promotes migration and invasion in a dose-dependent manner, and RON inhibition by monoclonal antibody reverses these effects. RON activation leads to E-cadherin loss and nuclear translocation of beta-catenin (consistent with EMT).\",\n      \"method\": \"Western blot for phospho-MAPK and phospho-AKT, migration/invasion assay, RON monoclonal antibody blockade, E-cadherin immunofluorescence, beta-catenin localization\",\n      \"journal\": \"Cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple signaling and phenotypic readouts, antibody blockade confirms RON specificity, single lab\",\n      \"pmids\": [\"17311308\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"RON positively regulates production of angiogenic chemokines in prostate cancer cells through NF-κB signaling. RON knockdown decreases NF-κB activation and angiogenic chemokine production; Ron overexpression in LNCaP cells increases chemokines, which can be abrogated by NF-κB inhibition. RON knockdown reduces endothelial cell chemotaxis in vitro and reduces tumor microvessel density in vivo.\",\n      \"method\": \"shRNA knockdown, NF-κB activity assay, chemokine ELISA, endothelial cell chemotaxis assay, orthotopic xenograft with microvessel density\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — NF-κB pathway mapped with both knockdown and overexpression, in vitro and in vivo validation, single lab\",\n      \"pmids\": [\"19838218\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"A novel RON isoform (P5P6), arising from partial splicing of exons 5 and 6 and lacking the first extracellular IPT domain, is constitutively phosphorylated, localizes to cytoplasm and traffics to plasma membrane, and activates AKT (and MAPK in some cell types). P5P6 transforms NIH3T3 cells and induces tumorigenicity in immortalized human pancreatic duct epithelial (HPDE) cells.\",\n      \"method\": \"RT-PCR, mass spectrometry peptide confirmation, Western blot, subcellular fractionation, kinase inhibitor, NIH3T3 transformation assay, in vivo tumor formation\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — protein isoform confirmed by MS, constitutive activation and localization characterized biochemically, transformation validated in vitro and in vivo, single lab\",\n      \"pmids\": [\"26477314\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The mouse Ron gene contains 19 exons spanning ~13.2 kb. Two promoter regions (nucleotides -585 to -465 and -465 to -285) are critical for Ron expression in epithelial cells, and gel mobility shift assays indicate specific protein binding at -585 to -508 (negative regulation) and -375 to -285 (positive regulation).\",\n      \"method\": \"Genomic library screening, primer extension, deletion reporter gene constructs (CAT assay), transient transfection, gel mobility shift assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter elements defined by deletion analysis with gel shift confirmation, single lab\",\n      \"pmids\": [\"9467940\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MST1R/RON is a heterodimeric receptor tyrosine kinase (35 kDa alpha + 150 kDa beta chains) activated by its specific ligand MSP, which induces beta-chain transautophosphorylation and recruits multiple downstream signaling cascades including PI3K/AKT, MAPK/ERK, c-Src, FAK, beta-catenin/TCF, and NF-κB; RON forms non-covalent complexes with MET on the cell surface enabling bidirectional transphosphorylation and cross-talk with EGFR, IGF-1R, and the EpoR, and can also translocate to the nucleus under hypoxia to directly activate c-JUN transcription; in macrophages, MSP/RON signaling suppresses inflammatory responses by inducing SOCS1 to inhibit STAT1, blocking NF-κB/Adam17-dependent TNF-α production, and upregulating arginase I via AP-1 to promote M2 polarization, while also regulating CD80/PD-L1 surface expression to modulate antitumor immunity; constitutively active truncated and alternatively spliced RON isoforms (sfRON, RONDelta160, RONDelta165, P5P6) drive EMT through SLUG-mediated E-cadherin repression and activate AKT-dependent oncogenic programs, and RON/MSP promotes metastasis through a PI3K→MBD4 epigenetic reprogramming pathway.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"MST1R (RON) is a heterodimeric receptor tyrosine kinase whose intracellular β-chain is activated by the HGF-homologue MSP, driving epithelial DNA synthesis, migration, proliferation, and survival [#0, #1]. Ligand binding requires the receptor sema domain, and a soluble sema fragment acts as a dominant-negative antagonist [#5]. Activated RON couples to a branched signaling network — FAK, c-Src/MAPK, JNK, and PI3K/AKT — in which c-Src/MAPK and FAK drive proliferation while PI3K/AKT confers anti-apoptotic and motility outputs [#8, #19], and engages the β-catenin/Tcf axis to induce c-myc and cyclin D1 during oncogenic transformation [#3]. RON cooperates with other receptor tyrosine kinases: it forms non-covalent surface complexes with MET enabling bidirectional transphosphorylation, and RON transactivation contributes to MET oncogene addiction [#2, #13]; it also physically associates with and is transphosphorylated by EGFR and IGF-1R [#6, #16]. Oncogenic point mutations and constitutively active truncated/spliced isoforms (sf-RON, P5P6, RONΔ165) signal ligand-independently through AKT and repress E-cadherin via SLUG to drive EMT and tumorigenesis [#4, #7, #30, #24], and RON/MSP promotes metastasis through a PI3K→MBD4 epigenetic reprogramming pathway requiring MBD4 glycosylase activity [#17]. Under hypoxia, RON translocates to the nucleus, interacts with HIF-1α, and directly activates c-JUN transcription in a kinase-dependent manner [#20]. In macrophages, MSP/RON signaling is broadly immunosuppressive: it induces SOCS1 to inhibit IFN-γ/STAT1 responses [#10], blocks NF-κB- and Adam17-dependent TNF-α production [#12, #14], upregulates arginase I via an AP-1/Fos mechanism [#11], and modulates CD80/PD-L1 surface expression to restrain antitumor immunity [#26]. RON additionally activates osteoclasts through a SRC-convergent pathway driving cancer-associated bone destruction [#25].\"\n,\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Established RON as a bona fide receptor tyrosine kinase and identified MSP as its specific ligand, defining the core receptor-ligand axis distinct from the HGF/MET system.\",\n      \"evidence\": \"Immunoprecipitation, in vitro kinase assay, radioligand cross-linking, and reciprocal ligand-specificity controls in transfected epithelial cells\",\n      \"pmids\": [\"8062829\", \"7939629\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream effector cascades not yet mapped\", \"Physiological tissue contexts unaddressed\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Defined the genomic structure and transcriptional control elements of the Ron gene, providing the basis for understanding context-specific expression.\",\n      \"evidence\": \"Genomic library screening, deletion-reporter CAT assays, and gel mobility shift assays of mouse promoter regions\",\n      \"pmids\": [\"9467940\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific trans-acting transcription factors not identified\", \"Human promoter not characterized in this study\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Resolved the branched intracellular signaling architecture downstream of RON, separating proliferative from survival and motility outputs.\",\n      \"evidence\": \"In vitro kinase assays with pharmacological inhibitors and dominant-negative constructs across MSP time-courses\",\n      \"pmids\": [\"10080538\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct adaptor docking events not mapped\", \"Single-lab pathway dissection\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Showed that oncogenic RON mutants transform cells and metastasize, and that β-catenin/Tcf is a required downstream oncogenic effector, linking RON activation to transcriptional programs.\",\n      \"evidence\": \"Oncogenic mutant transfection, β-catenin phosphorylation, Tcf reporter assays, NIH3T3 transformation, and in vivo metastasis models\",\n      \"pmids\": [\"11486025\", \"11593422\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of β-catenin tyrosine phosphorylation not defined\", \"Relevance of specific mutations to human tumors not established\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Demonstrated that RON and MET form surface complexes with bidirectional transphosphorylation, establishing cross-talk within the scatter-factor receptor subfamily.\",\n      \"evidence\": \"Kinase-inactive mutants, cell-surface cross-linking, phosphosite mapping, and dominant-negative focus-formation assays\",\n      \"pmids\": [\"10871856\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of MET-RON complexes not defined\", \"In vivo relevance not addressed in this study\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identified the immunoregulatory anti-apoptotic role of RON in macrophages, mediated by PI3K-dependent suppression of NO and p53.\",\n      \"evidence\": \"Primary macrophage apoptosis assays with wortmannin and dominant-negative PI3K p85\",\n      \"pmids\": [\"11818458\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct PI3K recruitment site on RON not mapped\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Showed that constitutively active truncated sf-RON drives EMT through SLUG-mediated E-cadherin repression, revealing how aberrant RON isoforms produce aggressive phenotypes.\",\n      \"evidence\": \"Retroviral transduction, kinase assays, morphological and anchorage-independent growth assays with SLUG analysis\",\n      \"pmids\": [\"15289319\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of SLUG induction by RON not defined\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Placed RON downstream of the erythropoietin receptor in erythroid progenitor expansion via constitutive Gab1 association, broadening RON's physiological signaling partnerships.\",\n      \"evidence\": \"Co-IP, phosphorylation assays, EpoR epistasis, and ex vivo progenitor expansion assays\",\n      \"pmids\": [\"14982882\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct physical EpoR-RON interaction not shown\", \"Differentiation block mechanism unexplained\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Defined RON-mediated suppression of IFN-γ/STAT1 responses via SOCS1 induction, with genetic epistasis confirming the immunosuppressive output in vivo.\",\n      \"evidence\": \"Primary macrophage STAT1/CIITA assays, SOCS1 induction, and RON/IFN-γR double-knockout rescue\",\n      \"pmids\": [\"18684919\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking RON kinase to SOCS1 transcription not defined\", \"Human macrophage relevance not tested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Revealed ligand-independent RON signaling modes (survival, spreading) mediated by Src family kinases, distinguishing them from MSP-dependent proliferation and migration.\",\n      \"evidence\": \"RON overexpression in MCF-10A cells with Src inhibition and phenotypic assays with/without MSP\",\n      \"pmids\": [\"18836480\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Source of MSP-independent activation not defined\", \"Single isogenic system\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified RON as a repressor of HIV-1 transcription operating at NF-κB recruitment and Pol II elongation checkpoints, an unexpected transcriptional regulatory role.\",\n      \"evidence\": \"ChIP for Pol II and elongation factors at the HIV LTR, HDAC inhibitor treatment, and nucleosome remodeling analysis\",\n      \"pmids\": [\"18209063\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct nuclear role of RON in this repression not established\", \"Single-lab mechanism\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Characterized a soluble antagonist isoform (RONΔ90) generated by exon skipping, demonstrating endogenous negative regulation of RON activation.\",\n      \"evidence\": \"RT-PCR, cDNA cloning, recombinant protein, and phosphorylation/migration inhibition assays\",\n      \"pmids\": [\"19519771\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo abundance and regulation of RONΔ90 unknown\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Linked RON to tumor angiogenesis through NF-κB-driven angiogenic chemokine production in prostate cancer.\",\n      \"evidence\": \"shRNA knockdown and overexpression, NF-κB assays, chemokine ELISA, endothelial chemotaxis, and orthotopic microvessel density\",\n      \"pmids\": [\"19838218\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct RON-to-NF-κB signaling intermediates not mapped\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Mapped RON-induced arginase I expression to an AP-1/Fos promoter mechanism driving M2-like macrophage polarization and tumor growth in vivo.\",\n      \"evidence\": \"Arg1 promoter analysis, Fos ChIP at the AP-1 site, MAPK assays, and Ron(-/-) tumor models\",\n      \"pmids\": [\"21810604\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stat6-independence mechanism not fully resolved\", \"Human tumor-associated macrophage data limited\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Established RON as a negative regulator of TNF-α production and shedding in alveolar macrophages via NF-κB/IκB and Adam17 control.\",\n      \"evidence\": \"Primary alveolar macrophage NF-κB assays, IκB Western, and Adam17 expression analysis\",\n      \"pmids\": [\"19487969\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of Adam17 downregulation not defined\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identified RON as an upstream activator of mutant PI3K in colon cancer, with knockdown sensitizing cells to apoptosis and reducing metastasis.\",\n      \"evidence\": \"siRNA knockdown, PI3K activity and AKT assays, apoptosis assays, and orthotopic metastasis models in PIK3CA-mutant cells\",\n      \"pmids\": [\"19224914\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct RON-PI3K coupling mechanism not defined\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Dissected opposing cell-type-specific roles of RON in liver injury using conditional knockouts, showing hepatocyte versus Kupffer cell contributions.\",\n      \"evidence\": \"Hepatocyte- and macrophage-specific Cre deletion, conditioned-media transfer, and in vivo liver injury models\",\n      \"pmids\": [\"21520175\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of divergent cell-type outputs not fully defined\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstrated that MET-addicted cancers transactivate RON, making RON a functional component of MET oncogene addiction and a co-target.\",\n      \"evidence\": \"MET-specific kinase inhibitors, antibody-induced MET shedding, RON shRNA, clonogenic assays, and xenografts\",\n      \"pmids\": [\"21212418\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution of RON to MET-driven phenotype variable\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Established unidirectional IGF-1R-to-RON transphosphorylation driving STAT3 activation and migration in pancreatic cancer.\",\n      \"evidence\": \"MudPIT proteomics, co-IP, RON shRNA/kinase inhibitor, scratch migration, and STAT3 assays\",\n      \"pmids\": [\"21565828\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of IGF-1R-RON interaction not defined\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Showed EBV LMP1 drives RON expression via NF-κB binding to the RON promoter, supporting B-cell transformation, linking viral oncogenesis to RON.\",\n      \"evidence\": \"NF-κB promoter binding, LMP1 CTAR1 mapping, shRNA, and knockdown-rescue proliferation assays\",\n      \"pmids\": [\"21659546\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct NF-κB binding site not finely mapped\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identified a RON-plectin-ITGB4 complex whose MSP-induced disruption of hemidesmosome anchoring promotes PI3K-dependent migration.\",\n      \"evidence\": \"MudPIT, co-IP, shRNA, migration assays, and PI3K/MEK inhibition in pancreatic cancer cells\",\n      \"pmids\": [\"22275185\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Stoichiometry and direct contacts within the complex not defined\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defined a PI3K→MBD4 epigenetic reprogramming pathway as a mechanistic driver of RON/MSP-mediated metastasis, with MBD4 glycosylase activity required.\",\n      \"evidence\": \"shRNA, MBD4 catalytic mutant rescue, methylation profiling, PI3K inhibition, and PDX in vivo metastasis models\",\n      \"pmids\": [\"24388747\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which MBD4 produces locus-specific methylation changes not resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Revealed a non-canonical nuclear function for RON under hypoxia, interacting with HIF-1α and directly activating c-JUN transcription in a kinase-dependent manner.\",\n      \"evidence\": \"Cell fractionation, co-IP, c-JUN promoter ChIP, kinase-dead mutant, reporter, and hypoxic functional assays\",\n      \"pmids\": [\"24903148\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of RON nuclear translocation not defined\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Characterized the constitutively active P5P6 splice isoform lacking the first IPT domain, demonstrating AKT-driven transformation and tumorigenicity.\",\n      \"evidence\": \"RT-PCR, MS peptide confirmation, fractionation, kinase inhibitor, NIH3T3 transformation, and in vivo tumor formation\",\n      \"pmids\": [\"26477314\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of constitutive activation upon IPT loss not defined\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Established RON signaling in osteoclast precursors as a SRC-convergent, RANKL-complementary driver of cancer-mediated bone destruction with clinical biomarker support.\",\n      \"evidence\": \"Genetic and pharmacological RON inhibition across multiple mouse osteolysis models with clinical bone-turnover biomarker data\",\n      \"pmids\": [\"28123075\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct osteoclast RON effectors beyond SRC convergence not mapped\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Linked macrophage RON activation to immune checkpoint regulation, showing RON inhibition synergizes specifically with anti-CTLA-4 for tumor eradication.\",\n      \"evidence\": \"Flow cytometry of CD80/PD-L1, genetic/pharmacological RON inhibition, orthotopic tumors, and combination immunotherapy\",\n      \"pmids\": [\"30228950\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of selectivity for anti-CTLA-4 over anti-PD-1 not resolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified HNRNPA2B1 as the splicing factor producing the pro-EMT RONΔ165 isoform via exon 11 exclusion, connecting alternative splicing to AKT-driven EMT.\",\n      \"evidence\": \"CRISPR/Cas9 knockout, minigene splicing reporter, EMT marker analysis, and rescue overexpression\",\n      \"pmids\": [\"32669614\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Regulation of HNRNPA2B1 in tumors not addressed\", \"Single-lab study\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the diverse RON-activating inputs (MSP, MET/EGFR/IGF-1R transactivation, hypoxia-induced nuclear translocation, constitutive splice isoforms) are integrated and selectively coupled to distinct downstream programs in a given cell type remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model of input-output specificity\", \"Structural basis of RON nuclear translocation and isoform constitutive activation undefined\", \"Mechanism connecting RON kinase output to specific transcriptional/epigenetic effectors incompletely mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 2, 8, 13]},\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [1, 5]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [20]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 1, 2, 30]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [20]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [30]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 8, 2]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [4, 13, 17]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [10, 11, 12, 26]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [20, 21]}\n    ],\n    \"complexes\": [\"MET-RON receptor complex\", \"RON-plectin-ITGB4 complex\"],\n    \"partners\": [\"MET\", \"EGFR\", \"IGF1R\", \"GAB1\", \"PLEC\", \"ITGB4\", \"HIF1A\", \"HNRNPA2B1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}